The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD - 03/03/21
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 12 |
| Iconografia | 4 |
| Video | 0 |
| Altro | 0 |
Highlights |
• | Intestinal microbiota plays an important role in the occurrence and development of liver diseases. |
• | Numerous mechanisms concerning the effect of intestinal microbiota on NAFLD and ALD have been report; for example, changes in the bacterial composition and number, breaks the intestinal barrier, allows for the translocation of the bacteria, and then leads to the activation of an inflammatory response. |
• | Intestinal microbiota metabolites are also impact liver health. |
• | The use of antibiotics, probiotics, prebiotics and fecal microbiota transplantation (FMT) has been shown to suppress liver disease progression in models including mice and humans. |
Abstract |
Introduction |
Liver diseases are currently common disorders worldwide. Especially, the proportion of patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) is growing globally. An increasing number of studies have revealed a close relationship between the intestinal microbiota and the development of NAFLD and ALD. A better understanding of the role of intestinal microbiota and the intestine-liver axis thus might lead to the development novel therapies for the treatment of these diseases.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Nonalcoholic fatty liver disease, Alcoholic liver disease, Intestinal microbiota, Intervention
Mappa
Vol 135
Articolo 111235- marzo 2021 Ritorno al numero
Articolo precedente
- COVID-19 and inflammatory bowel disease: A pathophysiological assessment
- Chunxiu Yang, Shu-Yuan Xiao
- Processed meat products with added plant antioxidants affect the microbiota and immune response in C57BL/6JRj mice with cyclically induced chronic inflammation
- Stina Burri, Kajsa Granheimer, Marine Rémy, Vandana Tannira, Yunjeong So, Kimmo Rumpunen, Eva Tornberg, Pamela Canaviri Paz, Elisabeth Uhlig, Elin Oscarsson, Anne-Marie Rohrstock, Milladur Rahman, Åsa Håkansson
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?